Summary
This Form 8-K/A filing by Gilead Sciences, Inc. (GILD) provides updated financial information related to its acquisition of Myogen, Inc. The primary purpose is to file the historical financial statements of Myogen and the unaudited pro forma combined financial information of Gilead and Myogen, which were initially omitted from the original 8-K filing. This amendment allows investors to see the financial impact of the acquisition as if it had occurred at earlier dates. The acquisition, completed on November 17, 2006, was a cash tender offer for all outstanding Myogen shares, with remaining shares converted to $52.50 cash. The report details the preliminary purchase price allocation, including significant amounts allocated to goodwill and purchased in-process research and development (IPR&D). The IPR&D allocation is largely attributed to Myogen's late-stage product candidates, ambrisentan for pulmonary arterial hypertension and darusentan for resistant hypertension.
Key Highlights
- 1Gilead Sciences completed the acquisition of Myogen, Inc. on November 17, 2006, for $2.44 billion in cash, stock options, and transaction costs.
- 2The acquisition is accounted for as a business combination, with Myogen becoming a wholly-owned subsidiary of Gilead.
- 3A significant portion of the purchase price, $2.06 billion, was allocated to purchased in-process research and development (IPR&D), primarily for ambrisentan and darusentan.
- 4The preliminary purchase price allocation includes $107.9 million for goodwill.
- 5The filing includes unaudited pro forma condensed combined financial statements, presenting the combined financial position and results of operations as if the acquisition occurred earlier.
- 6The acquisition expands Gilead's presence into the respiratory and cardiopulmonary therapeutic areas.
- 7The IPR&D allocation for ambrisentan and darusentan was based on discounted future cash flow projections, acknowledging significant development and regulatory risks.